REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
今後の臨床試験
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied Practiceまだ募集していません
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCまだ募集していません
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata Veronaまだ募集していません
-
University of Wisconsin, MadisonAlkermes, Inc.まだ募集していません
-
Virginia Commonwealth Universityまだ募集していません
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount Sinaiまだ募集していませんケタミン | fMRI | うつ病 - 大うつ病性障害 | rTMS | 治療抵抗性うつ病 (TRD)アメリカ
-
Weill Medical College of Cornell UniversityBD2 LLCまだ募集していませんfMRI | 双極性障害(BD) | rTMS | 双極1うつ病アメリカ
-
Yale UniversityNational Institute of Mental Health (NIMH)まだ募集していません
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge募集褐色細胞腫 | 褐色細胞腫/傍神経節腫 | 褐色細胞腫、転移性 | 悪性褐色細胞腫 | 褐色細胞腫および傍節腫(PPGL)イギリス
-
Carl Zeiss Meditec-Dublin CoCe募集網膜上膜 | 網膜疾患 | 乾燥性加齢黄斑変性症 | 硝子体網膜異常 | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium (RPE) Atrophyアメリカ
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical University募集